Cognizant Shared Investigator Platform for Life Sciences Reaches Major Milestone in Accelerating Drug Discovery

Rhea-AI Summary

Cognizant (Nasdaq: CTSH) announced its Shared Investigator Platform (SIP) has surpassed 100,000 users across 84 countries, highlighting its essential role in clinical trials during the COVID-19 pandemic. The platform, utilized by major biopharmaceutical companies, enhances collaboration and reduces site activation cycle time by 50%. Launched in 2016, SIP connects trial sponsors and medical professionals, streamlining processes crucial for drug development. This milestone underscores the platform's value in accelerating innovative therapies and improving patient care.

Positive

• SIP surpassing 100,000 users indicates strong market adoption.
• 50% reduction in site activation cycle time improves efficiency for users.
• Platform used by 7 major global biopharmaceutical companies enhances credibility.

Negative

• None.

TEANECK, N.J., July 21, 2020 /PRNewswire/ -- Cognizant (Nasdaq: CTSH) announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, has reached a new milestone of over 100,000 users in 84 countries. The platform has become increasingly critical to progressing clinical trials as prevailing social distancing norms have significantly curtailed in-person collaboration. Many of the companies utilizing the Shared Investigator Platform are working to accelerate COVID-19 therapies through virtual clinical trial processes.

The Shared Investigator Platform, in use by 7 of the largest global biopharmaceutical companies, links clinical trial sponsors and medical professionals by leveraging automation and remote access technology to increase the speed and efficiency of administering drug trials and bringing new therapies to market. The platform was first launched in 2016 as part of a collaboration between Cognizant and TransCelerate, a consortium of the world's largest biopharmaceutical organizations. These industry leaders collaboratively standardized clinical trial documents, training and start-up activities into a single shared environment to reduce costs and increase efficiency. 

Today, the Cognizant platform is used at over 19,000 trial-ready sites by medical and life sciences professionals to reduce administrative burdens that often slow the development and testing of life-saving clinical therapies. A global biopharmaceutical company using the platform realized a 50% reduction in critical site activation cycle time, based on an internal sponsor benchmark study.

"The COVID-19 pandemic has brought the processes of healthcare and life sciences firms to the forefront of global attention as the need to leverage advanced technologies for faster results and better care is paramount," said Srinivas Shankar, Senior Vice President and Global Head for Cognizant's Life Sciences business. "Our Shared Investigator Platform seamlessly enables communication and collaboration in clinical trials in areas such as site activation, document exchange, and safety notifications. Our milestone of 100,000 users across 84 countries is a testament to the value we are providing to those diligently working to accelerate innovative, effective treatments to patients in need."

Learn more about Cognizant's Shared Investigator Platform: https://www.cognizant.com/shared-investigator-platform

About Cognizant

Cognizant (Nasdaq: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 194 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.

View original content to download multimedia:http://www.prnewswire.com/news-releases/cognizant-shared-investigator-platform-for-life-sciences-reaches-major-milestone-in-accelerating-drug-discovery-301096354.html

SOURCE Cognizant

FAQ

What is the significance of Cognizant's Shared Investigator Platform milestone?

Cognizant's Shared Investigator Platform reaching over 100,000 users showcases its critical role in facilitating clinical trials, especially during the pandemic.

How has Cognizant's Shared Investigator Platform impacted clinical trials?

The platform has improved collaboration and efficiency, achieving a 50% reduction in site activation cycle time for users.

In how many countries is the Shared Investigator Platform utilized?

The Shared Investigator Platform is utilized in 84 countries globally.

Which companies use Cognizant's Shared Investigator Platform?

The platform is used by 7 of the largest global biopharmaceutical companies.